Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer

Molecular Cancer Research

Volumn 9, Issue 1, 2011, Pages 36-50

  Wang, Min ^a   Hu, Youji ^a   Amatangelo, Michael D ^a   Stearns, Mark E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; RIBOSOMAL PROTEIN S 2; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; COLONY FORMING UNIT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA PROCESSING;

ANIMALS; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

MUS;

EID: 78751489995     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0158     Document Type: Article

References (53)

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
2. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-70. (Pubitemid 47621223)
3. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7a regulates self renewal and tumorigenicity of breast cancer cells. Cell 2006;131:1109-23.
4. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120: 635-47.
5. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7a precursor loop mediates regulated microRNA processing. RNA 2008;14:1539-49.
6. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by LIN28. Science 2008;320:97-103.
7. Ohkia A, Hu Y, Wang M, Garcia FU, Stearns ME. Evidence for a prostate cancer associated diagnostic marker-1, PCADM-1: immunohistochemistry and in situ hybridization studies. Clin Can Res 2004;10:2452-8.
8. Wang M, Hu Y, Stearns ME. RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res 2004;28:6-14.
9. Wool IG. Extraribosomal functions of ribosomal proteins. Trends Biochem Sci 1996;21:164-5.
10. Chiao PJ, Shin DM, Sacks PG, Hong WK,, Tainsky MA. Elevated expression of the ribosomal protein S2 gene in human tumors. Mol Carcinog 1992;5:219-31.
11. Scott MR, Westphal KH, Rigby PW. Activation of mouse genes in transformed cells. Cell 1983;34:557-67.
12. Shin DM, Chiao PJ, Sacks PG, Shin HJ, Hong WK, Hittelman WN, et al. Activation of ribosomal protein S2 gene expression in a hamster model of chemically induced oral carcinogenesis. Carcinogenesis 1993;14:163-6.
13. Slynn G, Jenner D, Potts W, Elvin P, Morten J. Human cDNA sequence homologous to the mouse LLRep3 gene family. Nucleic Acids Res 1990;18:681-92.
14. Loging WT, Reisman D. Elevated expression of ribosomal protein genes L37, Rpp-1, and S2 in the presence of mutant p53. Cancer Epidemiol Biomark Prev 1999;8:1011-6.
15. Ardini E, Pesole G, Tagliabue E, Magnifico A, Castronovo V, Sobel ME, et al. The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol 1998:15:1017-25. (Pubitemid 28364455)
16. Kondoh N, Schweinfest CW, Henderson KW, Papas TS. Differential expression of S19 ribosomal protein, laminin-binding protein, and human lymphocyte antigen class I messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res 1992:52:791-6.
17. Wang M, Stearns ME. Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation 1991;48:115-25.
18. Goodyear SB, Amatangelo MD, Stearns ME. Dysplasia of human prostate CD133hi SPs in NOD-SCIDS is blocked by c-myc anti-sense. Prostate 2009;69:689-98.
19. Yasunaga Y, Nakamura K KD, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, et al. A novel human cancer culture model for the study of prostate cancer. Oncogene 2001;20:8036-41.
20. Blevins T. Northern blotting techniques for small RNAs. Methods Mol Biol 2010;631:87-107.
21. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual, Biotechnology; Molecular Biology; Biochemistry; Laboratory Manuals. Vol. 108. 3rd ed. Plainview, NY: Cold Spring Harbor Laboratory Press, 2003. 82-2.
22. Stearns M, Tran J, Zhang H, Francis MK, Sell C. Activated ras enhances insulin-like growth factor 1 mediated induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res 2005;65:2085-8.
23. Forooghian F, Macdonald IM, Heckenlively JR, Héon E, Gordon LK, Hooks JJ, et al. The need for standardization of anti-retinal antibody detection and measurement. Am J Ophthalmol 2008;146:489-95.
24. Croce CM. Role of TCL1 and ALL1 in human leukemias and development. Cancer Res 1999;59:1778s-83s.
25. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H., Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Can Res 2004;64:3753-6.
26. Meltzer PM. Cancer genomics: small RNAs with big impacts. Nature 2005;435:745-6.
27. Calin GA, Ferracin M, Cimmino A, Leva GD, Shimizu M, Wojcik SE, et al. MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
28. Lu J, Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
29. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33. (Pubitemid 351380068)
30. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5.
31. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
32. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006;29:903-6.
33. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008;14:2334-40.
34. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007;67:7713-22.
35. Shama S, Avni D, Frederickson R, Sonenberg N, Meyuhas O. Overexpression of initiation factor eIF-4E does not relieve the translational repression of ribosomal protein mRNAs in quiescent cells. Gene Expr 1995;4:241-52.
36. Nygard O, Nilsson L. Translational dynamics. Interactions between the translational factors, tRNA and ribosomes during eukaryotic protein synthesis. Eur J Biochem 1990;191:1-17.
37. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.
38. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007;6:5-12.
39. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME.The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010;17:19-36.
40. Maller Schulman BR, Liang X, Stahlhut C, Delconte C, Stefani G, Slack FJ. The let-7 microRNA target gene, Mlin41/Trim71 is required for mouse embryonic survival and neural tube closure. J Cell Cycle 2008;7:3935-42.
41. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-7.
42. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009;174:854-68.
43. Bushman EC, Nayak RN, Bushman W. Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue. J Urol 1995;153:233-7. (Pubitemid 24379848)
44. Agnantis NJ, Constantinidou AE, Papaevagelou M, Apostolikas N. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. Anticancer Res 1994;14:2135-40.
45. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009;174:854-68.
46. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to- mesenchymal transition. J Biol Chem 2008;283:33437-46.
47. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 Oncogene. Genes Dev 2007;21:1025-30.
48. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and HMGA2 enhances oncogenic transformation. Science 2007;315:1576-9.
49. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, et al. let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007;104:11400-5.
50. Piskounova E, Viswanathan SR, Janas M, Lapierre RJ, Daley GQ, Sliz P, et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein LIN28. J Biol Chem 2008;283:21310-4.
51. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009;28:347-58.
52. Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. LIN28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell 2008;32:276-84.
53. Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008;14:400-9.